- Aldeyra Therapeutics Enrolls First Patient in Phase 3 Clinical Trial Designed to Enable Potential Resubmission of New Drug Application of Reproxalap in Dry Eye Disease
- Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day
- Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024
- Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease
Key statistics
On Tuesday, Aldeyra Therapeutics Inc (ALDX:NAQ) closed at 3.79, 166.90% above the 52 week low of 1.42 set on Oct 16, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 3.82 |
---|---|
High | 3.95 |
Low | 3.70 |
Bid | 3.57 |
Offer | 3.91 |
Previous close | 3.79 |
Average volume | 301.99k |
---|---|
Shares outstanding | 59.41m |
Free float | 48.66m |
P/E (TTM) | -- |
Market cap | 225.18m USD |
EPS (TTM) | -0.5080 USD |
Data delayed at least 15 minutes, as of May 28 2024 21:00 BST.
More ▼